Aquestive Therapeutics filed an investor presentation for the Jefferies Global Healthcare Conference on November 16, 2026. The presentation provides updates on the regulatory status of Anaphylm (epinephrine) sublingual film, including the March 16, 2027 PDUFA goal date, and the commercial launch strategy for the product if approved.
Aquestive Therapeutics Director Richard J. Daly Buys $95.1K of Stock
Richard J. Daly, Director, bought 26,825 shares of Aquestive Therapeutics, Inc. at $3.54 a share, worth $95.1K in total on Nov 10, 2026. Shares held after the trade: 28,025 (+2235.4%).
Aquestive Therapeutics filed a corporate investor presentation for November 2026 to be used in meetings with institutional investors and analysts. The presentation provides updates on the regulatory status of Anaphylm (sublingual epinephrine) following its NDA resubmission, which has a PDUFA goal date of March 16, 2027, and the development of its AdrenaVerse pipeline including AQST-108.
Aquestive Therapeutics reported a net loss of $47.4 million for the nine months ended September 30, 2026, compared to a loss of $54.9 million in the prior year period. Total revenues increased to $35.8 million from $31.5 million, while the company recognized a $11.7 million loss on the extinguishment of debt following the redemption of its 13.5% Notes.
Aquestive Therapeutics reported Q3 2026 financial results and provided a regulatory update for its lead candidate Anaphylm, which has a PDUFA goal date of March 16, 2027. The company is preparing for a potential U.S. launch and plans to submit regulatory filings in Canada and the EU in late 2026 and early 2027.
Term
Q3 2026
“With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved. For decades, people at risk of anaphylaxis have had limited treatment options. We believe Anaphylm - designed to be easy to carry and use confidently whenever and wherever it may be needed - has the potential to address important unmet needs.”
Daniel Barber, President and Chief Executive Officer of Aquestive
Aquestive Therapeutics President and CEO Daniel Barber Sells $106K of Stock
Daniel Barber, President and CEO, sold 25,000 shares of Aquestive Therapeutics, Inc. at $4.22 a share, worth $106K in total on Oct 15, 2026. Shares held after the trade: 627,317 (-3.8%).
Aquestive Therapeutics announced that the FDA has accepted its NDA resubmission for Anaphylm (dibutepinephrine) sublingual film as complete and assigned a PDUFA goal date of March 16, 2027. The resubmission follows positive results from studies designed to address a prior Complete Response Letter, positioning Anaphylm to potentially become the first oral rescue medication for severe allergic reactions.
Aquestive Therapeutics Licensing Deal with Eton Pharmaceuticals, Inc. Worth $57.5M
Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for the treatment of seizure clusters in epilepsy patients. Aquestive received a $10 million upfront fee and is eligible for up to $47.5 million in regulatory and commercial milestones, plus mid-teens royalties on net sales. Aquestive will remain the exclusive manufacturer and supplier of the product for an initial 20-year term.
Aquestive Therapeutics appointed Richard J. Daly to its Board of Directors as a Class I director, effective October 14, 2026. Mr. Daly, a veteran life sciences executive with experience at AstraZeneca and Takeda, will receive an initial grant of 57,000 stock options as part of his non-employee director compensation package.
Aquestive Therapeutics filed a corporate investor presentation dated September 23, 2026, to be used in meetings with institutional investors and analysts. The presentation provides updates on the company's AdrenaVerse pipeline, including the regulatory status of Anaphylm (epinephrine) sublingual film following its NDA resubmission to the FDA and the development of AQST-108 for dermatologic indications.
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions. The resubmission addresses a prior Complete Response Letter by including new human factors and pharmacokinetic data, notably reducing the median pouch-opening time from 17 seconds to 3 seconds. The company also filed an investor presentation from the H.C. Wainwright 28th Annual Global Investor Conference.
Aquestive Therapeutics President and CEO Daniel Barber Sells $120K of Stock
Daniel Barber, President and CEO, sold 25,000 shares of Aquestive Therapeutics, Inc. at $4.82 a share, worth $120K in total on Sep 15, 2026. Shares held after the trade: 652,317 (-3.7%).